i Partnerships with Corporations | Partnerships | Acetylon Pharmaceuticals
Logo
Contact    |    Site Map    |    Careers

 

Partnerships with Corporations

Acetylon and Celgene Corporation have entered into an exclusive strategic collaboration to advance the science of epigenetics, including an upfront $100 million payment by Celgene to advance Acetylon’s clinical and pipeline programs, including the ongoing combination clinical trial of ricolinostat (ACY-1215) with Celgene’s best-in-class drug Revlimid® (lenalidomide) plus dexamethasone in multiple myeloma as well as combinations of ricolinostat with other leading anti-cancer agents including Velcade. Celgene has also received an exclusive option to acquire Acetylon on defined terms. Acetylon will remain in control of its development programs during the period of the option. Celgene is the pharmaceutical industry global leader in anti-cancer drugs indicated for the treatment of multiple myeloma and also has major international presence in treating other types of cancer. Previous acquisitions by Celgene have generally left intact the smaller company’s R&D and clinical trials staffing and clinical development strategies.

Please read the press release for more details.

Celgene Corporation also made an earlier, substantial strategic equity investment in Acetylon, receiving a Board observation right. Acetylon is currently investigating the combination of Celgene's class-leading myeloma drug, Revlimid® with Acetylon's selective HDAC6 inhibitor drug candidate, ricolinostat, in a Phase 1b clinical trial.

Please read the press release for more details.

Acetylon is currently investigating the combination of Celgene's further myeloma drug, Pomalyst® with Acetylon's selective HDAC6 inhibitor drug candidate, ricolinostat, in a Phase 2 clinical trial.

Please read the press release for more details.